Biologics/Immunotherapy News

Researchers identified an association between a self-reported history of high-risk allergy and an increased risk for allergic reactions after receipt of an mRNA COVID-19 vaccine.

Tezepelumab reduces exacerbations among patients who have severe asthma, including some types of asthma that lack other effective biologic therapies, according to a draft evidence report by the Institute for Clinical and Economic Review.

Benralizumab appeared effective for severe eosinophilic asthma in a real-world study of patients with and without chronic rhinosinusitis with nasal polyps, according to data published in The Journal of Allergy and Clinical Immunology.

Patients with mild to severe atopic dermatitis may benefit from long-term upadacitinib and topical corticosteroid treatment without any new safety risks, according to a study published in The Journal of Allergy and Clinical Immunology.

Approximately 1% of patients on peanut allergen powder oral immunotherapy developed eosinophilic esophagitis, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Patients with food allergies can avoid items that may be dangerous — or they can work with an allergist to develop an oral immunotherapy plan that would enable them to safely consume and enjoy previously dangerous foods.

Three currently available type 2 biologics approved for asthma appeared effective in treating chronic rhinosinusitis with nasal polyps, according to data published in The Journal of Allergy and Clinical Immunology: In Practice.

Awareness of oral immunotherapy for food allergy appeared low among those affected and pediatric caregivers, according to survey results published in The Journal of Allergy and Clinical Immunology: In Practice.

Continued daily treatment with Peanut Allergen Powder-dnfp after its first year improves safety and tolerability profiles, as well as clinical and immunological responses, according to a study published in Allergy.

Antihistamine premedication can improve the safety and efficacy of allergen immunotherapy, according to results of a meta-analysis published in Annals of Allergy, Asthma & Immunology.